The Online Investor
Home
Dividends
25 Safe Dividends
Stock Splits
Mergers & Acquisitions
Business Services/Equipment M&A

Construction M&A
   General Contractors & Builders M&A
Consumer Goods M&A
   Sporting Goods & Activities M&A
   Office Supplies M&A
   Food & Beverage M&A
   Beverages & Wineries M&A
   Cigarettes & Tobacco M&A
   Marijuana Stocks M&A
   Apparel Stores M&A
   Department Stores M&A
   Grocery & Drug Stores M&A
   Electronics Stores M&A
   Home Improvement Stores M&A
   Home Furnishing Stores M&A
   Auto Dealerships M&A
   Specialty Retail M&A
Consumer Services M&A
   Education & Training Services M&A
Energy M&A
   Oil & Gas Refining & Marketing M&A
   Oil & Gas Exploration & Production M&A
   Oil & Gas Equipment & Services M&A
Financial M&A
   Banking & Savings M&A
   Investment Brokerages M&A
   Investment Companies & Venture Capital M&A
   Asset Management M&A
   Credit Services & Lending M&A
   Life & Health Insurance M&A
   Insurance Brokers M&A
Healthcare M&A
   Drugs & Pharmaceuticals M&A
   Biotechnology M&A
   Diagnostics M&A
   Medical Instruments & Supplies M&A
   Hospital & Medical Practitioners M&A
Industrial M&A
   Chemicals M&A
   Specialty Chemicals M&A
   Defense M&A
   Aerospace & Defense M&A
   Construction Materials & Machinery M&A
   Industrial Machinery & Equipment M&A
Manufacturing M&A
   Home Furnishings & Furniture M&A
   Auto Manufacturers M&A
   Auto Parts M&A
   Textiles & Apparel M&A
Materials M&A
   Agricultural Chemicals M&A
   Rubber & Plastics M&A
   Paper & Forest Products M&A
   Packaging & Containers M&A
   Agriculture & Farm Products M&A
Media M&A
   Advertising M&A
   Television & Radio M&A
   Publishing & Printing M&A
Metals & Mining M&A
   Precious Metals M&A
   Non-Precious Metals & Non-Metallic Mining M&A
   Metals Fabrication & Products M&A
Real Estate M&A
   REITs M&A
Technology M&A
   Electronic Equipment & Products M&A
   3D Printing Stocks M&A
   Computers M&A
   Computer Peripherals M&A
   Application Software M&A
   Semiconductors M&A
   Information Technology Services M&A
Transportation M&A
   Air Services Other M&A
   Airlines M&A
   Trucking M&A
   Shipping M&A
   Railroads M&A
Travel & Entertainment M&A
   Hotels, Lodging, Restaurants & Travel M&A
   Entertainment M&A
Utilities M&A
   Waste Management M&A
   Communications Services M&A
   Electric Utilities M&A
   Gas Utilities M&A
   Water Utilities M&A
Mega Mergers
Daily M&A
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
Stock Buybacks
IPOs
Secondary Offerings
Top 20 Large Caps
Top 20 Biggest ETFs
Insider Buying
Top 25 Low PE Ratios
Analyst Actions
25 Top Analyst Picks
Articles
CAGR Calculator
Dunnan On Dollars
10 Pot Stocks
ETF Center
Knowledge Center
Retirement Center
Advertising Opportunities
Privacy Policy
Disclaimer Statement
Drugs & Pharmaceuticals M&A image Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Sat., Apr. 20, 12:47 AM Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.

This Slide: #51 of 100

Slide #51. Jazz Pharmaceuticals plc — Gentium S.p.A.

Acquirer: Jazz Pharmaceuticals plc (JAZZ)
Acquiree: Gentium S.p.A. (GENT)
Details: Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Gentium S.p.A. (Nasdaq: GENT) today announced that they have entered into a definitive agreement pursuant to which a subsidiary of Jazz Pharmaceuticals will make a cash tender offer of $57.00 per share for all outstanding Gentium ordinary shares and American Depositary Shares, in a transaction that is valued at approximately $1 billion.

Jazz Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious diseases with limited or no options. Co.'s primary marketed products are: Xyrem® (sodium oxybate) oral solution, for the treatment of both cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution, for the treatment of cataplexy or EDS in narcolepsy patients seven years of age and older; and Sunosi® (solriamfetol), to improve wakefulness in adult patients with EDS associated with narcolepsy or obstructive sleep apnea.

JAZZ SEC Filing Email Alerts Service


Open the JAZZ Page at The Online Investor »

Jazz Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious diseases with limited or no options. Co.'s primary marketed products are: Xyrem® (sodium oxybate) oral solution, for the treatment of both cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution, for the treatment of cataplexy or EDS in narcolepsy patients seven years of age and older; and Sunosi® (solriamfetol), to improve wakefulness in adult patients with EDS associated with narcolepsy or obstructive sleep apnea.

JAZZ SEC Filing Email Alerts Service


Open the GENT Page at The Online Investor »

JAZZ — Key Stats (updated 13 hours, 53 minutes ago)
Company Name:  Jazz Pharmaceuticals Plc
Stock buyback:  JAZZ buyback
Website:  www.jazzpharmaceuticals.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding JAZZ:  86
Total Market Value Held by ETFs:  $1.20B
Total Market Capitalization:  $6.79B
% of Market Cap. Held by ETFs:  17.65%
GENT — Key Stats (updated Mon., Mar. 3, 10:26 AM)
Company Name:  Gentium SpA
Website:  www.gentium.it
Sector:  Biotechnology
 

April 20, 2024  •  12:47 AM Eastern
Related Quotes
Quotes delayed 20 minutes

Email EnvelopeFree Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Drugs & Pharmaceuticals M&A - Slide 51 of 100 | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.